Botulinum neurotoxin for the treatment of migraine and other primary headache disorders

Dermatologic Clinics

Volumn 22, Issue 2, 2004, Pages 167-175

  Blumenfeld, Andrew M ^a   Dodick, David W ^b,c   Silberstein, Stephen D ^d  

^a Kaiser Permanente ^*  (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ANTINOCICEPTIVE AGENT; BOTULINUM TOXIN A; GLUTAMIC ACID; PROTEIN C FOS;

ANALGESIA; ANTINOCICEPTION; CLINICAL TRIAL; CLOSTRIDIUM BOTULINUM; DIPLOPIA; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; ECCHYMOSIS; GENE EXPRESSION; HEADACHE AND FACIAL PAIN; HUMAN; INJECTION SITE; INTRAFUSAL MUSCLE FIBER; LOW DRUG DOSE; MIGRAINE; MUSCLE SPINDLE; MUSCLE WEAKNESS; MYOFASCIAL PAIN; NERVE ENDING; NEUROMUSCULAR SYNAPSE; PRIORITY JOURNAL; PTOSIS; REVIEW; SIGNAL TRANSDUCTION; SPINAL CORD DORSAL HORN; TENSION HEADACHE;

BOTULINUM TOXIN TYPE A; HEADACHE; HUMANS; INJECTIONS, INTRAMUSCULAR; MIGRAINE DISORDERS; NEUROMUSCULAR AGENTS; SAFETY; TREATMENT OUTCOME;

EID: 2442449135     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(03)00105-0     Document Type: Review

References (31)

1. Lipton R.B., Stewart W.F., Diamond S., Diamond M.L., Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 41:2001;646-657
2. Menken M., Munsat T.L., Toole J.F. The global burden of disease study: implications for neurology. Arch Neurol. 57:2000;418-420
3. Hu X.H., Markson L.E., Lipton R.B., Stewart W.F., Berger M.L. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 159:1999;813-818
4. Thom T.J. Economic costs of neoplasms, arteriosclerosis, and diabetes in the United States. In Vivo. 10:1996;255-259
5. Weiss K.B., Gergen P.J., Hodgson T.A. An economic evaluation of asthma in the United States. N Engl J Med. 326:1992;862-866
6. Goadsby P.J., Lipton R.B., Ferrari M.D. Migraine: current understanding and treatment. N Engl J Med. 346:2002;257-270
7. Scher A.I., Stewart W.F., Liberman J., Lipton R.B. Prevalence of frequent headache in a population sample. Headache. 38:1998;497-506
8. Silberstein S., Mathew N., Saper J., Jenkins S. Botulinum toxin type A as a migraine preventive treatment. Headache. 40:2000;445-450
9. Silberstein S.D., Goadsby P.J. Migraine: preventive treatment. Cephalalgia. 22:2002;491-512
10. Gobel H., Heinze A., Heinze-Khun K., Jost W.H. Evidence-based medicine: botulinum toxin A in migraine and tension-type headache. J Neurol. 248(suppl 1):2001;34-38
11. Allergan Pharmaceuticals. BOTOX (botulinum toxin type A) prescribing information. Irvine, CA: Allergan Pharmaceuticals
12. Heckmann M., Ceballos-Baumann A.O., Plewig G. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med. 344:2001;488-493
13. Carruthers J., Carruthers A. Botulinum toxin (Botox) chemodenervation for facial rejuvenation. Facial Plast Surg Clin North Am. 9:2001;197-204
14. Tsui J.K.C., Eisen A., Stoessl A.J., Calne D.B. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet. 2:1986;245-247
15. Dunne J.W., Heye N., Dunne S.L. Treatment of chronic limb spasticity with botulinum toxin A. J Neurol Neurosurg Psychiatry. 58:1995;232-235
16. Klein A.W. Complications and adverse reactions with the use of botulinum toxin. Dis Mon. 48:2002;336-356
17. Brin M.F. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve. 20(suppl 6):1997;S146-S168
18. Rosales R., Arimura K., Takenaga S., Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve. 19:1996;488-495
19. Aoki R. The antinociceptive mechanism of action of botulinum toxin A. Presented at the American Headache Society 44th Annual Scientific Meeting. Seattle, WA, June 21-23, 2002
20. Burstein R., Yarnitsky D., Goor-Aryeh I., Ransil B.J., Bajwa Z.H. An association between migraine and cutaneous allodynia. Ann Neurol. 47:2000;614-624
21. Binder W.J., Brin M.F., Blitzer A., Schoenrock L.D., Pogoda J.M. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg. 123:2000;669-676
22. Mauskop A., Basdeo R. Botulinum toxin A is an effective prophylactic therapy for migraines. Cephalalgia. 20:2000;422
23. Eross E.G., Dodick D.W. The effects of botulinum toxin type A on disability in episodic and chronic migraine [abstract S108]. Presented at the American Headache Society 44th Annual Scientific Meeting. Seattle, WA, June 21-23, 2002
24. Blumenfeld A. Botulinum toxin type A (BOTOX) as an effective prophylactic treatment in headache [abstract 81]. Presented at the 6th headache congress: European Headache Federation. Istanbul, Turkey, June 26-30, 2002
25. Mauskop A. The use of botulinum toxin in the treatment of headaches. Curr Pain Headache Rep. 6:2002a;320-323
26. Mauskop A. Long-term use of botulinum toxin type A (BOTOX) in the treatment of episodic and chronic migraine headaches [abstract S105]. Presented at the American Headache Society 44th Annual Scientific Meeting. Seattle, WA, June 21-23, 2002
27. Mathew N.T., Kallasam J., Kaupp A., Meadors L. Disease modification in chronic migraine with botulinum toxin type A: long-term experience [abstract S107]. Presented at the American Headache Society 44th Annual Scientific Meeting. Seattle, WA, June 21-23, 2002
28. Miller T., Denny L. Retrospective cohort analysis of 48 chronic headache patients treated with botulinum toxin type A (BOTOX) in a combination fixed-injection-site and "follow the pain" protocol [abstract S138]. Presented at the American Headache Society 44th Annual Scientific Meeting. Seattle, WA, June 21-23, 2002
29. Barrientos N., Chana P. Efficacy and safety of botulinum toxin type A (BOTOX) in the prophylactic treatment of migraine [abstract S106]. Presented at the American Headache Society 44th Annual Scientific Meeting. Seattle, WA, June 21-23, 2002
30. Brin M.F., Binder W.J., Blitzer A., Schenrock L., Pogoda J.M. Botulinum toxin type A for pain and headache. Brin M.F., Hallett M., Jankovic J. Scientific and therapeutic aspects of botulinum toxin. 2002;233-250 Lippincott Williams & Wilkins, New York
31. Ondo W.G., Vuong K.D., Derman H.S. Botulinum toxin A (BOTOX) for chronic daily headache: a randomized placebo-controlled, parallel design study [abstract S131]. Presented at the American Headache Society 44th Annual Scientific Meeting. Seattle, WA, June 21-23, 2002